Abstract
Antagonists of growth hormone-releasing hormone (GH-RH), such as MZ-4-71 suppress the secretion of GH. These findings suggest that GH-RH antagonists could be used for the therapy of disorders characterized by excessive GH secretion. It has been also demonstrated that MZ-4-71 displays antidepressant effects in a modified forced swimming test in mice, exerts anxiolytic effects in an elevated plus maze test, improves memory consolidation in passive avoidance learning, and corrects the impairment of memory consolidation caused by β-amyloid (25-35) in mice. However, little is known about the mechanisms of action of MZ-4-71 on brain functions. In the present work, the involvement of the adrenergic, serotonergic and GABA-ergic receptors in the anxiolytic action of MZ-4-71 was studied in an elevated plus maze. Mice were pretreated with a nonselective α-adrenergic receptor antagonist, phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist, prazosin, an α2-adrenergic receptor antagonist, yohimbine, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, and a γ-aminobutyric acid subunit (GABA-A) receptor antagonist, bicuculline. Phenoxybenzamine, praz...Continue Reading
References
Feb 1, 1987·Neuropeptides·A Ottlecz, G Telegdy
Jan 1, 1984·Psychopathology·S J Enna
Sep 1, 1995·Endocrinology·S MatsubaraJ Takahara
Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·M ZarandiA V Schally
Feb 13, 2002·The Journal of Clinical Psychiatry·Marcio VersianiMario Savino
Oct 22, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ferenc ObalJames M Krueger
Feb 15, 2005·Hormones and Behavior·Lucia I ArwertMadeleine L Drent
Aug 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Laura B JaegerAndrew V Schally
Sep 8, 2005·Brain Research Bulletin·G TelegdyA Adamik
Nov 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Alexandre HavtCelia A Kanashiro
Aug 2, 2006·Treatments in Endocrinology·Jan Berend Deijen, Lucia I Arwert
Oct 13, 2006·Pituitary·Monica GolaAndrea Giustina
Dec 18, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Andrew V SchallyJörg B Engel
Oct 23, 2008·Neuroscience·E EnginC T Dickson
Jan 29, 2009·CNS Drugs·Martin A Katzman
Jul 18, 2009·Psychopharmacology·Elif Engin, Dallas Treit
Dec 8, 2010·Proceedings of the National Academy of Sciences of the United States of America·William A BanksAndrew V Schally
Dec 31, 2010·Current Opinion in Biotechnology·Matthias Heinemann, Uwe Sauer
Jun 16, 2011·Behavioural Brain Research·Gyula TelegdyAndrew V Schally
Sep 29, 2011·Expert Opinion on Pharmacotherapy·Jennifer A ReinholdFalk W Lohoff
Dec 27, 2011·Behavioural Brain Research·M TanakaG Telegdy
Citations
Jun 8, 2013·Behavioural Brain Research·G Telegdy, A Adamik
Jul 17, 2014·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Sheila LeoneLuigi Brunetti
Apr 7, 2015·Peptides·Andrew V Schally
Feb 8, 2014·Behavioural Brain Research·Gyula Telegdy, Miklós Jászberényi
Jul 31, 2013·Regulatory Peptides·G Telegdy, A Adamik
Jun 24, 2018·Endocrine Connections·Sheila LeoneLuigi Brunetti
Jan 22, 2020·Scientific Reports·Lucia RecinellaSheila Leone
Jul 3, 2013·Journal of Neurochemistry·Deepti NairDavid Gozal
Oct 10, 2018·Endocrine Connections·Sheila LeoneLuigi Brunetti
Aug 1, 2021·Molecular Psychiatry·Lucia RecinellaSheila Leone